Watermark

BGB-A317-203

Completed

A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-203

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20170119

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan